ADARx Pharmaceuticals' IPO terms, filed September 21, 2026, target a $1.69–1.74 billion valuation via 21.9 million shares priced at $15–17, implying a midpoint near $1.7 billion with AbbVie committing up to $100 million in a concurrent placement tied to its prior $335 million collaboration. This anchors sentiment around the $1.5–2 billion bins amid a wave of biotech debuts, while the company's Phase 3 onvuzosiran candidate for hereditary angioedema, cash runway into 2030, and siRNA pipeline provide fundamental support. Evenly matched probabilities across bins reflect uncertainty over post-pricing demand, broader biotech trading multiples, and potential first-day volatility ahead of the expected late-September Nasdaq listing under ADRX.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado<$1.5 mil millones 25%
$1.5 mil millones-$1.75 mil millones 24%
$3B+ 24%
No hay salida a bolsa antes de noviembre de 2026 23%
NUEVO
NUEVO
25 sep 2026
<$1.5 mil millones
25%
$1.5 mil millones-$1.75 mil millones
24%
$1.75B-$2B
12%
$2 mil millones-$2.25 mil millones
12%
$2.25B-$2.5B
12%
$2.5B-$3B
12%
$3B+
24%
No hay salida a bolsa antes de noviembre de 2026
23%
<$1.5 mil millones 25%
$1.5 mil millones-$1.75 mil millones 24%
$3B+ 24%
No hay salida a bolsa antes de noviembre de 2026 23%
NUEVO
NUEVO
25 sep 2026
<$1.5 mil millones
$0 Vol.
25%
$1.5 mil millones-$1.75 mil millones
$0 Vol.
24%
$1.75B-$2B
$0 Vol.
12%
$2 mil millones-$2.25 mil millones
$0 Vol.
12%
$2.25B-$2.5B
$0 Vol.
12%
$2.5B-$3B
$0 Vol.
12%
$3B+
$0 Vol.
24%
No hay salida a bolsa antes de noviembre de 2026
$0 Vol.
23%
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals' IPO terms, filed September 21, 2026, target a $1.69–1.74 billion valuation via 21.9 million shares priced at $15–17, implying a midpoint near $1.7 billion with AbbVie committing up to $100 million in a concurrent placement tied to its prior $335 million collaboration. This anchors sentiment around the $1.5–2 billion bins amid a wave of biotech debuts, while the company's Phase 3 onvuzosiran candidate for hereditary angioedema, cash runway into 2030, and siRNA pipeline provide fundamental support. Evenly matched probabilities across bins reflect uncertainty over post-pricing demand, broader biotech trading multiples, and potential first-day volatility ahead of the expected late-September Nasdaq listing under ADRX.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado abierto: Sep 23, 2026, 6:43 PM ET
Volumen
$0Fecha de finalización
25 sep 2026Mercado abierto
Sep 23, 2026, 6:43 PM ETResolver
0x69c47de9d...This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals' IPO terms, filed September 21, 2026, target a $1.69–1.74 billion valuation via 21.9 million shares priced at $15–17, implying a midpoint near $1.7 billion with AbbVie committing up to $100 million in a concurrent placement tied to its prior $335 million collaboration. This anchors sentiment around the $1.5–2 billion bins amid a wave of biotech debuts, while the company's Phase 3 onvuzosiran candidate for hereditary angioedema, cash runway into 2030, and siRNA pipeline provide fundamental support. Evenly matched probabilities across bins reflect uncertainty over post-pricing demand, broader biotech trading multiples, and potential first-day volatility ahead of the expected late-September Nasdaq listing under ADRX.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$0Fecha de finalización
25 sep 2026Mercado abierto
Sep 23, 2026, 6:43 PM ETResolver
0x69c47de9d...ADARx Pharmaceuticals' IPO terms, filed September 21, 2026, target a $1.69–1.74 billion valuation via 21.9 million shares priced at $15–17, implying a midpoint near $1.7 billion with AbbVie committing up to $100 million in a concurrent placement tied to its prior $335 million collaboration. This anchors sentiment around the $1.5–2 billion bins amid a wave of biotech debuts, while the company's Phase 3 onvuzosiran candidate for hereditary angioedema, cash runway into 2030, and siRNA pipeline provide fundamental support. Evenly matched probabilities across bins reflect uncertainty over post-pricing demand, broader biotech trading multiples, and potential first-day volatility ahead of the expected late-September Nasdaq listing under ADRX.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes